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The European Antimicrobial Resistance Surveillance Network (EARS-Net) collects data on carbapenem resistance
from invasive bacterial infections. Increasing percentages of carbapenem resistance in K. pneumoniae isolates were
reported from progressively more countries in Europe between 2005 and 2010. A trend analysis showed increasing
trends for Greece, Cyprus, Hungary and Italy (p < 0.01). EARS-Net collects data on invasive bacterial isolates, which
likely correspond to a fraction of the total number of infections. Increasing reports of community cases suggest that
dissemination of carbapenem-resistant K. pneumoniae has penetrated into the community. Good surveillance and
infection control measures are urgently needed to contain this spread.
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β-lactamasesBackground
European Antimicrobial Resistance Surveillance Network
(EARS-Net) data originate from clinical microbio-
logical laboratories across Europe, reporting anti-
microbial susceptibility results for seven invasive
bacterial pathogens. These include two of the Entero-
bacteriaceae, Klebsiella pneumoniae (K. pneumoniae),
a common cause of healthcare-associated infections,
and Escherichia coli (E. coli), a frequent cause of
community-acquired urinary tract infections, which is
widely disseminated in the environment. In general,
carbapenem resistance in Enterobacteriaceae can be
conferred by the presence of various mechanisms of
resistance, including the carbapenemases, which are
β-lactamases that can hydrolyse most β-lactams, in-
cluding the carbapenems. Good prevalence data are
not always available for carbapenemase-producing
Enterobacteriaceae (CPE) and since carbapenem-
resistant K. pneumoniae isolates are frequently found
to be carbapenemase-producing, carbapenem resist-
ance is frequently used a surrogate marker for the
presence of carbapenemases.* Correspondence: anna-pelagia.magiorakos@ecdc.europa.eu
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distribution, and reproduction in any mediumInfections with CPE were first reported in Europe as
imported cases or outbreaks in healthcare systems
from endemic countries within Europe and beyond
[1,2]. The epidemiology of CPE in Europe is now
changing and an increasing number of community-
associated, autochthonous cases are reported [1,3].
Interestingly enough, recent publications describe the
detection of CPE from environmental sources, i.e.
KPC-producing E. coli and OXA-48-producing Serratia
marcescens from environmental water samples in Por-
tugal [4] and Morocco [5], respectively, suggesting that
sources of CPE go beyond the hospital, into the com-
munity and environment.
Data from EARS-Net showed increasing percentages
of carbapenem resistance in K. pneumoniae isolates be-
tween 2005 and 2010 from progressively more countries
in Europe. A trend analysis in the EARS-Net Annual
Report 2011 showed an increasing trend for Europe,
overall [6]. Some countries were not included in this
analysis because their laboratories did not report con-
tinuously during 2005–2010. Among the remaining
countries one country, Greece, contributed 27% of the
total K. pneumoniae isolates and 98% of carbapenem-
resistant K. pneumoniae isolates and drove most of
the observed increasing trend. Our study aimed to
look at and separately analyse the trends for thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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nem resistance in K. pneumoniae isolates to EARS-
Net from 2005 to 2010.
Methods
Susceptibility testing results of invasive, carbapenem-
resistant K. pneumoniae isolates (not including inter-
mediately susceptible), were extracted from the
EARS-Net database for 2005–2010. Laboratories included
in the analysis were those that had reported antimicrobial
susceptibility results for K. pneumoniae to EARS-Net for at
least three years during 2005–2010. Trend analyses, using
number of isolates and not percentages, were performed
using the Cochran-Armitage test for trend and confirmed
by Poisson regression.
Results
Eighteen countries reported at least one carbapenem-
resistant K. pneumoniae isolate in the six-year period and
of these countries, six showed an increasing or decreasing
trend. The number of countries with ≥1% carbapenem re-
sistance amongst invasive K. pneumoniae isolates increased
from 2, in 2005 (Greece, 27.8%; Germany, 3.1%) to 5 in
2010 (Greece, 49.8%; Cyprus, 16.4%; Italy, 12.5%; Hungary,
5.9%; Portugal, 2.2%). Significant increasing trends were
observed for Greece, Cyprus, Hungary and Italy (p < 0.01).
Germany, which did not report any carbapenem-resistantFigure 1 Carbapenem-resistant K. pneumoniae trends from the Europ
2005 to 2010. Percentages and trends of invasive carbapenem-resistant K.
European Antimicrobial Resistance Surveillance Network (EARS-Net) from 2
laboratories reported carbapenem susceptibility data in K. pneumoniae isola
or higher for any of these years and for which a significantly increasing or
percentage resistance of 1% or higher, increased from 2 in 2005 (Greece, 2
12.5%; Hungary, 5.9%; Portugal, 2.2%). Significant increasing trends were ob
which did not report any carbapenem-resistant K. pneumoniae isolate in 20K. pneumoniae isolate in 2010, showed a decreasing trend
(p < 0.01) (Figure 1).
Discussion
Increasing trends of resistance to carbapenems in K. pneu-
moniae isolates in Europe, even if currently observed only
in a few countries, are worrisome because carbapenems
are last-line antibiotics. Additionally, when carbapenem re-
sistance is due to presence of carbapenemases, accumula-
tion of other resistance traits to aminoglycosides and
fluoroquinolones often render these CPE extensively drug-
resistant (XDR) or pandrug-resistant (PDR), leaving few or
no effective treatment options [1,7,8]. These bacteria dis-
seminate rapidly within hospitals, following breaches in in-
fection control measures. Infections with CPE are
associated with high patient morbidity and mortality [9,10].
Our knowledge of the magnitude and geographical
distribution of carbapenem- resistant Enterobacteriaceae
(CRE) is incomplete and EARS-Net data likely represent
only “the tip of the iceberg” for a number of reasons.
EARS-Net collects only data on invasive bacterial isolates
and since these bacteria can also cause non-invasive infec-
tions, EARS-Net data likely correspond to only a fraction
of the total number of these. Supporting this, are recent
reports of autochthonous and community cases of CPE
[1,3], suggesting the dissemination and penetration of CPE
beyond the hospital, into the community. Lastly, variationsean Antimicrobial Resistance Surveillance Network (EARS-Net),
pneumoniae isolates from European countries reporting to the
005 to 2010. The 6 countries shown in this figure are those whose
tes for at least three years during 2005–2010, had a percentage of 1%
decreasing trend was observed. The number of countries with a
7.8%; Germany, 3.1%) to 5 in 2010 (Greece, 49.8%; Cyprus, 16.4%; Italy,
served for Greece, Cyprus, Hungary and Italy (p < 0.01). Germany,
10, showed a decreasing trend (p < 0.01).
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cation of CRE and CPE, may not allow all cases to be
reported to EARS-Net.
Heightened concern for this public health threat has
spurred the publication of systematic reviews, risk assess-
ments [1] and guidance documents [1,11-13], which ad-
dress the control and spread of CPE. These underscore
that good surveillance and early warning systems at all
levels, active screening of high-risk patients, notification
of health authorities, strict implementation of targeted
infection control measures in healthcare systems and the
practice of prudent use of antimicrobials are key ele-
ments to halt the spread of CPE.
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